Kamada (KMDA) Receivables (2012 - 2026)
Kamada (KMDA) posted quarterly Receivables of $40.7 million for Q1 2026, up 19.94% year-on-year from $33.9 million in Q1 2025, and up 24.46% on a QoQ basis from $32.7 million in Q4 2025.
Kamada (KMDA) Receivables (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Receivables for 15 consecutive years, with $40.7 million the latest figure, recorded in Q1 2026.
- Quarterly Receivables rose 19.94% year-over-year to $40.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.7 million (up 19.94% YoY) and the FY2025 annual result came in at $32.7 million, up 20.56% from the prior year.
- Receivables rose to $40.7 million in Q1 2026 per KMDA's latest filing, from $32.7 million in the prior quarter.
- Over the last five years, Receivables for KMDA reached as high as $40.7 million in Q1 2026 and fell as low as $24528.0 in Q1 2023.
- A 5-year average of $26.1 million and a median of $27.7 million in 2023 frame the typical range for Receivables.
- Annual changes were most pronounced in 2023 — Receivables tumbled 99.92% — and 2024, when it soared 102908.81%.
- Year by year, Receivables stood at $27.8 million in 2022, then dropped by 7.03% to $25.8 million in 2023, then increased by 4.84% to $27.1 million in 2024, then rose by 20.56% to $32.7 million in 2025, then advanced by 24.46% to $40.7 million in 2026.
- According to Business Quant data, Receivables over the past three periods registered $40.7 million, $32.7 million, and $35.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 2.99 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 3.39 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.51 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 6.46 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 312.00 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 15.29 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 3.58 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 768.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 1.15 Bn |
| 10 | Kamada | 401.22 Mn | 328.07 Mn | 19.12 Mn | 40.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 40.65 Mn |
| Dec 31, 2025 | 32.66 Mn |
| Sep 30, 2025 | 35.32 Mn |
| Jun 30, 2025 | 35.21 Mn |
| Mar 31, 2025 | 33.89 Mn |
| Dec 31, 2024 | 27.09 Mn |
| Sep 30, 2024 | 20.85 Mn |
| Jun 30, 2024 | 31.17 Mn |
| Mar 31, 2024 | 25.27 Mn |
| Dec 31, 2023 | 25.84 Mn |
| Sep 30, 2023 | 26.76 Mn |
| Jun 30, 2023 | 27.66 Mn |
| Mar 31, 2023 | 24,528.00 |
| Dec 31, 2022 | 27.80 Mn |
| Sep 30, 2022 | 30,881.00 |
| Jun 30, 2022 | 24.15 Mn |
| Mar 31, 2022 | 29.44 Mn |
| Dec 31, 2021 | 44.03 Mn |
| Sep 30, 2021 | 30.94 Mn |
| Jun 30, 2021 | 30.19 Mn |